ABBOTT LABORATORIES — Director's Dealing 2019

Jun 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-06-10

Reporting Person: Earnhardt Lisa D (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-10	Common shares without par value	A	17431	—	Acquired	17431	Direct
2019-06-10	Common shares without par value	A	39515	—	Acquired	56946	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-10	Option (right to buy)	$80.98	A	91367	Acquired	2029-06-09	Common shares (91367)	Direct

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with the award vesting on June 10, 2022. The award includes the right to have shares withheld for tax purposes.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,455 on June 10, 2020, 30,456 on June 10, 2021, and 30,456 on June 10, 2022.